Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-20 6:59 pm Purchase | 2026-02-12 | 13D | Immunic, Inc. IMUX | BIOTECHNOLOGY VALUE FUND L P | 13,630,601 9.990% | 3,845,423 (+39.30%) | Filing History |
| 2026-02-18 7:49 pm Purchase | 2026-02-10 | 13G | Sutro Biopharma, Inc. STRO | BIOTECHNOLOGY VALUE FUND L P | 1,251,788 7.600% | 1,251,788 (New Position) | Filing History |
| 2026-02-17 4:32 pm Purchase | 2025-12-31 | 13G | Xencor, Inc. XNCR | BIOTECHNOLOGY VALUE FUND L P | 7,133,720 9.990% | 2,514,379 (+54.43%) | Filing History |
| 2026-02-17 4:30 pm Purchase | 2025-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BIOTECHNOLOGY VALUE FUND L P | 3,411,993 3.900% | 1,168,334 (+52.07%) | Filing History |
| 2026-02-17 4:28 pm Sale | 2025-12-31 | 13G | Tyra Biosciences, Inc. TYRA | BIOTECHNOLOGY VALUE FUND L P | 2,127,665 4.000% | -1,816,529 (-46.06%) | Filing History |
| 2026-02-17 4:27 pm Purchase | 2025-12-31 | 13G | Tenax Therapeutics, Inc. TENX | BIOTECHNOLOGY VALUE FUND L P | 768,200 9.990% | 427,540 (+125.50%) | Filing History |
| 2026-02-17 4:25 pm Sale | 2025-12-31 | 13G | Septerna, Inc. SEPN | BIOTECHNOLOGY VALUE FUND L P | 1,720,782 3.800% | -2,675,342 (-60.86%) | Filing History |
| 2026-02-17 4:23 pm Sale | 2025-12-31 | 13G | SAB Biotherapeutics, Inc. SABS | BIOTECHNOLOGY VALUE FUND L P | 4,761,906 9.100% | -405,712 (-7.85%) | Filing History |
| 2026-02-17 4:21 pm Sale | 2025-12-31 | 13G | Palvella Therapeutics, Inc. PVLA | BIOTECHNOLOGY VALUE FUND L P | 879,009 7.100% | -302,185 (-25.58%) | Filing History |
| 2026-02-17 4:19 pm Purchase | 2025-12-31 | 13G | Invivyd, Inc. IVVD | BIOTECHNOLOGY VALUE FUND L P | 25,525,000 9.000% | 9,525,000 (+59.53%) | Filing History |
| 2026-02-17 4:18 pm Purchase | 2025-12-31 | 13G | Structure Therapeutics Inc. GPCR | BIOTECHNOLOGY VALUE FUND L P | 10,437,066 4.900% | 825,315 (+8.59%) | Filing History |
| 2026-02-17 4:14 pm Sale | 2025-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE | BIOTECHNOLOGY VALUE FUND L P | 3,835,886 5.900% | -1,824,246 (-32.23%) | Filing History |
| 2026-02-17 4:12 pm Purchase | 2025-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BIOTECHNOLOGY VALUE FUND L P | 5,847,281 9.990% | 1,214,532 (+26.22%) | Filing History |
| 2026-02-17 4:10 pm Purchase | 2025-12-31 | 13G | Cullinan Therapeutics, Inc. CGEM | BIOTECHNOLOGY VALUE FUND L P | 5,918,481 9.990% | 122,048 (+2.11%) | Filing History |
| 2026-02-17 4:07 pm Purchase | 2025-12-31 | 13G | Avalo Therapeutics, Inc. AVTX | BIOTECHNOLOGY VALUE FUND L P | 1,904,257 9.990% | 446,106 (+30.59%) | Filing History |
| 2026-01-30 6:39 pm Sale | 2026-01-28 | 13D | Repare Therapeutics Inc. RPTX | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -10,333,600 (Position Closed) | Filing History |
| 2025-12-15 6:07 pm Purchase | 2025-12-11 | 13D | Kymera Therapeutics, Inc. KYMR | BIOTECHNOLOGY VALUE FUND L P | 6,867,809 8.500% | 1,036,638 (+17.78%) | Filing History |
| 2025-11-24 5:05 pm Unchanged | 2025-11-20 | 13D | Repare Therapeutics Inc. RPTX | BIOTECHNOLOGY VALUE FUND L P | 10,333,600 24.000% | 0 (Unchanged) | Filing History |
| 2025-11-19 5:10 pm Purchase | 2025-11-17 | 13D | Inventiva S.A. IVA | BIOTECHNOLOGY VALUE FUND L P | 9,569,863 4.990% | 1,024,364 (+11.99%) | Filing History |
| 2025-11-14 4:26 pm Sale | 2025-09-30 | 13G | Zymeworks Inc. ZYME | BIOTECHNOLOGY VALUE FUND L P | 3,938,641 5.200% | -669,294 (-14.52%) | Filing History |